BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Sofogianni A, Filippidis A, Chrysavgis L, Tziomalos K, Cholongitas E. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. World J Hepatol 2020; 12(8): 493-505 [PMID: 32952876 DOI: 10.4254/wjh.v12.i8.493]
URL: https://www.wjgnet.com/1007-9327/full/v12/i8/493.htm
Number Citing Articles
1
Demelza Emmerton, Ahmed Abdelhafiz. Newer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older peopleHospital Practice 2021; 49(3): 164 doi: 10.1080/21548331.2021.1905414
2
Khaoula Errafii, Olfa Khalifa, Neyla S. Al-Akl, Abdelilah Arredouani. Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid MetabolismBiomedicines 2022; 10(5): 1020 doi: 10.3390/biomedicines10051020
3
Poonam Yadav, Amit Khurana, Jasvinder Singh Bhatti, Ralf Weiskirchen, Umashanker Navik. Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspectivePharmacological Research 2022; 184: 106426 doi: 10.1016/j.phrs.2022.106426
4
Rajaa Nahra, Tao Wang, Kishore M. Gadde, Jan Oscarsson, Michael Stumvoll, Lutz Jermutus, Boaz Hirshberg, Philip Ambery. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b StudyDiabetes Care 2021; 44(6): 1433 doi: 10.2337/dc20-2151
5
Lampros G. Chrysavgis, Spyridon Kazanas, Konstantina Bafa, Sophia Rozani, Maria-Evangelia Koloutsou, Evangelos Cholongitas. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease NomenclatureInternational Journal of Molecular Sciences 2024; 25(7): 3832 doi: 10.3390/ijms25073832
6
Maria Corina Plaz Torres, Ariel Jaffe, Rachel Perry, Elisa Marabotto, Mario Strazzabosco, Edoardo G. Giannini. Diabetes medications and risk of HCCHepatology 2022; 76(6): 1880 doi: 10.1002/hep.32439
7
Alan J. Sinclair, Daniel Pennells, Ahmed H. Abdelhafiz. Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus—a choice determined by metabolic phenotypeAging Clinical and Experimental Research 2022; 34(9): 1949 doi: 10.1007/s40520-022-02142-8
8
Ja Young Jeon, Hae Jin Kim. Stroke Revisited: Diabetes in StrokeStroke Revisited 2021; : 167 doi: 10.1007/978-981-16-5123-6_14
9
Olufunto O. Badmus, Sarah A. Hillhouse, Christopher D. Anderson, Terry D. Hinds, David E. Stec. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathwaysClinical Science 2022; 136(18): 1347 doi: 10.1042/CS20220572
10
Ameng Shi, Ting Li, Ying Zheng, Yahua Song, Haitao Wang, Na Wang, Lei Dong, Haitao Shi. Chlorogenic Acid Improves NAFLD by Regulating gut Microbiota and GLP-1Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.693048
11
Veronika A. Prikhodko, Natalia N. Bezborodkina, Sergey V. Okovityi. Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug CandidatesBiomedicines 2022; 10(2): 274 doi: 10.3390/biomedicines10020274
12
Alan J. Sinclair, Ahmed H. Abdelhafiz. Metabolic Impact of Frailty Changes Diabetes TrajectoryMetabolites 2023; 13(2): 295 doi: 10.3390/metabo13020295
13
Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapySignal Transduction and Targeted Therapy 2024; 9(1) doi: 10.1038/s41392-024-01931-z
14
Daniela Maria Tanase, Evelina Maria Gosav, Daniela Petrov, Alina Ecaterina Jucan, Cristina Mihaela Lacatusu, Mariana Floria, Claudia Cristina Tarniceriu, Claudia Florida Costea, Manuela Ciocoiu, Ciprian Rezus. Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic TargetsDiagnostics 2021; 11(11): 2053 doi: 10.3390/diagnostics11112053
15
Hae Jin Kim. Recent Updates on Glucagon-Like Peptide 1 Receptor AgonistThe Journal of Korean Diabetes 2021; 22(2): 126 doi: 10.4093/jkd.2021.22.2.126
16
Maja Cigrovski Berkovic, Tanja Rezic, Ines Bilic-Curcic, Anna Mrzljak. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?World Journal of Clinical Cases 2022; 10(20): 6759-6768 doi: 10.12998/wjcc.v10.i20.6759
17
Omar Hegazi, Samer Alalalmeh, Moyad Shahwan, Ammar Jairoun, Mansour Alourfi, Ghfran Bokhari, Abdullah Alkhattabi, Saeed Alsharif, Mohannad Aljehani, Abdulmalik Alsabban, Mohammad Almtrafi, Ysear Zakri, Abdullah AlMahmoud, Khalid Alghamdi, Ahmed Ashour, Nasser Alorfi. Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov AnalysisDiabetes, Metabolic Syndrome and Obesity 2024; : 545 doi: 10.2147/DMSO.S448476
18
Khamis Al Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, Angelo Maria Patti, Khalid Al Waili, Khalid Al Rasadi, Marcello Ciaccio, Manfredi Rizzo. Metabolic dysfunction-associated fatty liver disease: current therapeutic strategiesFrontiers in Nutrition 2024; 11 doi: 10.3389/fnut.2024.1355732
19
Manisha Yadav, Smriti Verma, Purnima Tiwari, Madhav Nilakanth Mugale. Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectivesLife Sciences 2024; 353: 122934 doi: 10.1016/j.lfs.2024.122934
20
J. Bojunga, A. Beckerbauer. Diabetes und Gastroenterologie – Update 2021Der Diabetologe 2021; 17(5): 528 doi: 10.1007/s11428-021-00780-6
21
Hao Wang, Qianqian Ma, Youpeng Chen, Ling Luo, Junzhao Ye, Bihui Zhong. Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trialsObesity Reviews 2024; 25(6) doi: 10.1111/obr.13727
22
Joanna Michałowska, Ewa Miller-Kasprzak, Paweł Bogdański. Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical PerspectiveNutrients 2021; 13(2): 351 doi: 10.3390/nu13020351
23
Ana Petrovic, Dunja Igrec, Karla Rozac, Kristina Bojanic, Lucija Kuna, Tea Omanovic Kolaric, Vjera Mihaljevic, Renata Sikora, Robert Smolic, Marija Glasnovic, George Y. Wu, Martina Smolic. The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLDCurrent Issues in Molecular Biology 2023; 45(6): 4544 doi: 10.3390/cimb45060288
24
Mai Salah Nour, Zeinab Abd El-Hay Sakara, Nawal Awad Hasanin, Shereen Mohamed Hamed. Histological and immunohistochemical study of the effect of liraglutide in experimental model of non-alcoholic fatty liver diseaseEgyptian Journal of Basic and Applied Sciences 2023; 10(1): 342 doi: 10.1080/2314808X.2023.2204258